Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

[Effects of prolonged exposure to antiretroviral treatment in Tunisian patients assessed by the HIV-1 resistance genotypic test].

Jlizi A, Azzouzi A, Bouzayen I, Slim A, Ben Rejeb S, Garbouj M, Ben Ammar El Gaaied A.

Med Mal Infect. 2009 Sep;39(9):707-13. doi: 10.1016/j.medmal.2008.10.009. French.

PMID:
19028037
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

[Evaluating the therapeutic care of HIV infection in Tunisia].

Jlizi A, Slim A, Benammar Elgaaied A, Ben Rejab S, Ben Chaabane T, Letaief-Omezzine A, Chakroun M, Garbouj M.

Tunis Med. 2008 Jun;86(6):534-9. French.

PMID:
19216443
4.

Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, Segondy M.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):36-43. Erratum in: J Acquir Immune Defic Syndr 2001 Apr 1;26(4):395.

PMID:
11176267
5.

Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.

Jlizi A, Ben Ammar El Gaaied A, Slim A, Tebourski F, Ben Mamou M, Ben Chaabane T, Letaief-Omezzine A, Chakroun M, Garbouj M, Ben Rejeb S.

Arch Virol. 2008;153(6):1103-8. doi: 10.1007/s00705-008-0104-z.

PMID:
18483694
6.
7.

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

Adjé C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respess R, Wiktor SZ, Chorba T, Nkengasong JN; UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire..

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):501-6.

PMID:
11391173
8.

Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.

Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, Piroj W, Tiensuwan M, Chantratita W.

Infection. 2007 Apr;35(2):81-8.

PMID:
17401711
9.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
10.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8.

11.

Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing.

Birch C, Middleton T, Hales G, Cooper D, Law M, Crowe S, Hoy J, Emery S.

J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):57-61.

PMID:
12514414
12.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
13.

Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.

Bilé EC, Adjé-Touré C, Borget MY, Kalou M, Diomande F, Chorba T, Nkengasong JN.

J Clin Virol. 2005 Jan;32(1):60-6.

PMID:
15572008
14.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
15.

Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients.

Zöllner B, Feucht HH, Weitner L, Adam A, Schröter M, Schäfer P, Laufs R.

J Clin Virol. 2001 Apr;21(1):37-45.

PMID:
11255096
16.

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.

AIDS. 1998 Jun 18;12(9):1015-20.

PMID:
9662197
17.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
18.

Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

Medeiros MS, Arruda EA, Guerrant RL, Brown CC, Lima AA.

Braz J Infect Dis. 2007 Oct;11(5):451-5.

19.

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M.

J Med Virol. 2003 Jan;69(1):1-6.

PMID:
12436471
20.

The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.

Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, Minoli L, Sighinolfi L, Nasta P, Suter F; MASTER Data Base Cohort..

Antivir Ther. 2006;11(7):923-9.

PMID:
17302255

Supplemental Content

Support Center